Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | GBA1 | P04062 | 3/20 | 0.39 |
| ▸ | CASP2 | P42575 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451353 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL17706676 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL1525803 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL3449857 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL11055256 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL3451377 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL3449805 | 1.00 | EPHX1 (0.52) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL2928776 | 0.97 | — | — | |
| SCHEMBL23270896 | 0.91 | EPHX1 (0.61) | EPHX1TSHRALDH1A1THRBADH1B | |
| SCHEMBL8416435 | 0.91 | EPHX1 (0.61) | EPHX1TSHRALDH1A1THRBADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100487-A1 | UNDERFILL MATERIAL, CURED PRODUCT, SEMICONDUCTOR PACKAGE, AND METHOD FOR MANUFACTURING SAME | 旭化成株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026100491-A1 | EPOXY RESIN COMPOSITION, CURED OBJECT, UNDERFILL MATERIAL, ADHESIVE, AND SEMICONDUCTOR PACKAGE AND PRODUCTION METHOD THEREFOR | 旭化成株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2025028611-A1 | CURING AGENT FOR EPOXY RESINS, EPOXY RESIN COMPOSITION, CURED OBJECT, SEALING MATERIAL, AND ADHESIVE | 旭化成株式会社 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025028605-A1 | CURING AGENT, EPOXY RESIN COMPOSITION, CURED OBJECT, SEALING MATERIAL, AND ADHESIVE | 旭化成株式会社 | 2025-02-06 | — | — | WO | disclosed |
| WO-2025028598-A1 | CURING AGENT FOR EPOXY RESINS, EPOXY RESIN COMPOSITION, CURED OBJECT, SEALING MATERIAL, AND ADHESIVE | 旭化成株式会社 | 2025-02-06 | — | — | WO | disclosed |
| US-20250034319-A1 | EPOXY RESIN COMPOSITION, CURED PRODUCT, ENCAPSULANT AND ADHESIVE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-01-30 | — | — | US | disclosed |
| US-20230212132-A1 | AMINIMIDE COMPOUND, AMINIMIDE COMPOSITION, CURING AGENT, EPOXY RESIN COMPOSITION, METHOD FOR PRODUCING AMINIMIDE COMPOUND, ENCAPSULANT, AND ADHESIVE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023127800-A1 | EPOXY RESIN COMPOSITION, CURED PRODUCT, SEALING MATERIAL, AND ADHESIVE | 旭化成株式会社 | 2023-07-06 | — | — | WO | disclosed |
| CN-115803323-A | Aminoimide compound, aminimide composition, curing agent, epoxy resin composition, method for producing aminimide compound, sealing material, and adhesive | 旭化成株式会社 | 2023-03-14 | — | — | CN | disclosed |
| US-11234456-B2 | Modified carbon material and method for reducing carbonaceous material ignition temperature | CHINA TOBACCO YUNNAN INDUSTRIAL CO., LTD (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20210395789-A1 | Materials and Methods for Producing Cardiolipin-Like Phospholipids | LOCUS SOLUTIONS IPCO, LLC | 2021-12-23 | — | — | US | disclosed |
| WO-2021216325-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC AND CARDIOVASCULAR DISEASES | UNIVERSITY OF ROCHESTER (US) | 2021-10-28 | — | — | WO | disclosed |
| US-10971284-B2 | Power and communications cable for coiled tubing operations | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-3772515-A1 | STABLE POLYMORPHIC FORM OF 6-FLUORO-9-METHYL-9H-SS-CARBOLINE AND USES THEREOF | Audiocure Pharma GmbH (DE) | 2021-02-10 | — | — | EP | disclosed |
| EP-1861120-B1 | USE OF AN INFLUENZA VIRUS AND AN OIL-IN-WATER EMULSION ADJUVANT TO INDUCE CD4 T-CELL AND/OR IMPROVED B-MEMORY CELL RESPONSE | GLAXOSMITHKLINE BIOLOG SA (BE) | 2016-05-25 | — | — | EP | disclosed |
| CN-101039719-A | Mascara compositions and methods of use | AVON PROD INC (US) | 2007-09-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212132-A1 | AMINIMIDE COMPOUND, AMINIMIDE COMPOSITION, CURING AGENT, EPOXY RESIN COMPOSITION, METHOD FOR PRODUCING AMINIMIDE COMPOUND, ENCAPSULANT, AND ADHESIVE | ITGAL, VCL, RPL39 | EPHX1 765/4885TSHR 4744/4885ALDH1A1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.